NCCN Flash Updates: NCCN Guidelines^® Updated for Vulvar Cancer

NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®) for Cancer in People with HIV. These NCCN Guidelines^® are currently available as Version 2.2021. 

Link directly to the Updates section of the NCCN Guidelines:
NCCN Guidelines for Cancer in People with HIV

• The Discussion section has been updated to reflect the changes in the algorithm (MS-1).

Previous updates to the NCCN Guidelines for Cancer in People with HIV can be found in the UPDATES section of the current version.

 

NCCN has published updates to the NCCN Guidelines for Vulvar Cancer. These NCCN Guidelines are currently available as Version 3.2021. 

Link directly to the Updates section of the NCCN Guidelines:
NCCN Guidelines for Vulvar Cancer

•  The Discussion section has been updated to reflect the changes in the algorithm (MS-1).

Previous updates to the NCCN Guidelines for Vulvar Cancer can be found in the UPDATES section of the current version.



NCCN has published updates to the NCCN Guidelines for Hematopoietic Cell Transplantation. These NCCN Guidelines are currently available as Version 2.2021. 

Link directly to the Updates section of the NCCN Guidelines:
NCCN Guidelines for Hematopoietic Cell Transplantation

• The Discussion section has been updated to reflect the changes in the algorithm. (MS-1)

Previous updates to the NCCN Guidelines for Hematopoietic Cell Transplantation can be found in the UPDATES section of the current version.



NCCN has published updates to the NCCN Guidelines and the NCCN Drugs & Biologics Compendium (NCCN Compendium^®) for Bladder Cancer. These NCCN Guidelines are currently available as Version 3.2021. 

Link directly to the Updates section of the NCCN Guidelines:
NCCN Guidelines for Bladder Cancer
 

• Principles of Systemic Therapy 
  • Subsequent-line systemic therapy for locally advanced or metastatic disease (Stage IV),
    • Other recommended regimens, sacituzumab govitecan-hziy was added as a category 2A recommendation.

Previous updates to the NCCN Guidelines for Bladder Cancer can be found in the UPDATES section of the current version.
 

NCCN has published updates to the NCCN Chemotherapy Order Templates (NCCN Templates^®) for Bladder Cancer to reflect the currently published NCCN Guidelines for Bladder Cancer v3.2021. 

• The following NEW NCCN Template^® has been published:
  • BLA75: Sacituzumab govitecan-hziy

For the complete updated versions of the NCCN Guidelines, NCCN Guidelines with NCCN Evidence Blocks™, the NCCN Drugs & Biologics Compendium (NCCN Compendium^®), the NCCN Biomarkers Compendium^®, the NCCN Chemotherapy Order Templates (NCCN Templates^®), the NCCN Radiation Therapy Compendium™, and the NCCN Imaging Appropriate Use Criteria (NCCN Imaging AUC™), please visit NCCN.org.

To view the NCCN Guidelines for Patients^®, please visit NCCN.org/patientguidelines.

Free NCCN Guidelines apps for iPhone, iPad, and Android devices are now available! Visit NCCN.org/apps.

About NCCN Flash Updates™

NCCN Flash Updates™ is a subscription service from NCCN that provides timely notification of updated and new information appearing in the NCCN Guidelines, the NCCN Compendium^®, and other NCCN Content.

Subscribe to NCCN Flash Updates™

Please note: 1. Third Party Content. The NCCN Content may contain content (such as figures, tables or illustrations) that NCCN licenses from third parties as displayed on NCCN Third Party Content FTP site: ftp://ftp1.nccn.org (To access: user name:content; password is NCCNcontent) (“Third Party Content”). Licensee shall be solely responsible for obtaining permissions from each such third party to use any such Third Party Content in the Permitted Works.

Access information on permissions and licensing of NCCN Content

Users may unsubscribe from Flash Updates at any time contacting us. NOTE: The subscription fee for NCCN Flash Updates™ is non-refundable.